

## Ardelyx to Present at the 2015 Leerink Global Healthcare Conference

February 9, 2015

FEELONI, Call, Feb. 3, 2015 PRifferenties' - Analysis, tie. (NASDAD, ARDI), a direct stage between class company sourced on another real, gastrointesinal, and metabolic diseases, today announced that Mise Raab, Plesident and Chef Executive Officer and David Rosenbaum Ph.D., Serior Voc President, Drug Development, will present a company overview at the 2015 Learns Clobel Headmann Conference at 80 at. 25 for Serior Serior Voc President, Drug Development, will present a company overview at the 2015 Learns Clobel Headmann Conference at 80 at. 25 for Serior Serior Voc President, Drug Development, will present a company overview at the 2015 Learns Clobel Headmann Conference at 80 at. 25 for Serior Voc President, Drug Development, will present a company overview at the 2015 Learns Clobel Headmann Conference at 80 at. 25 for Serior Voc President, Drug Development, will present a company overview at the 2015 Learns Clobel Headmann Conference at 80 at. 25 for Serior Voc President, Drug Development, will present a company overview at the 2015 Learns Clobel Headmann Conference at 80 at. 25 for Serior Voc President, Drug Development, will present a company overview at the 2015 Learns Clobel Headmann Conference at 80 at. 25 for Serior Voc President, Drug Development, and Drug Development, Drug Develop



## About Ardelyx, Inc.

Analysis as a dinicial-stage biopharmaceutical company locused on the discovery, development and commercialization of innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointesinal tract to read cards-renal, gastrointesinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and coase-flictent manner, to discover and design not enabling it. The company has developed and coase-flictent manner, to discover and design not enabling it. The company has developed and coase-flictent manner, to discover and design not enabling it. The company has developed and coase-flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The coase flictent manner, to discover and design not enabling it. The real manner, to discover and enabling it manner, to discover and design not enabling it. The real manner, to discover and design not enabling it manner, to discover and design not enabling it in a rapid and coase flictent manner, to discover and design not enabling it manner. The company has developed and coase flictent manner, to discover and design not enabling it manner. The company has developed and coase flictent manner, to discover and design not enabling it manner. The company has developed and coase flictent manner, to discover and design not enabling it manner,

Logo - http://photos.pmewswire.com/prnh/20140619/119451

To view the original version on PR Newswire, visit:http://ww SOURCE Ardelyx, Inc. News Provided by Acquire Media